登录新浪财经APP 搜索【信披】查看更多考评等级 ● 本次权益变动前后，公司控股股东持股数额、比例未发生变化，公司控股股东及实际控制人均未发生 变化。 一、本次权益变动基本情况 本次权益变动前，Alliance Healthcare由Walgreens Boots Alliance, Inc.（以下简称"WBA"，一家于美国特 拉华州成立的公司）间接持有其100%的股权。近日，WBA与Blazing Star Merger Sub, Inc.发生合并重 组，重组完成后，WBA自美国纳斯达克交易所退市，合并重组后由Blazing Star Investors, LLC（以下简 称"BSI"）间接持有Alliance Healthcare 100%的股权。就前述WBA重组之详情，可于美国证券交易委员 会网站（http://www.sec.gov）查阅相关披露文件。 本次权益变动前，Alliance Healthcare由WBA间接控制，股权结构如下图所示： ■ 本次权益变动后，Alliance Healthcare由合并重组完成后的主体BSI间接控制，股权结构如下图所示： 本公司董事会及全体董事保证本公告内容不存 ...

关于持股 5%以上股东间接权益变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? Alliance Healthcare Asia Pacific Limited（以下简称"Alliance Healthcare"） 直接持有南京医药股份有限公司（以下简称"公司"）144,557,431 股股份，占公 司总股本的 11.04%。本次权益变动系 Alliance Healthcare 的间接股东发生变化所 致。 ? 本次权益变动前后，Alliance Healthcare 持有的公司股份数额未发生变化。 ? 本次权益变动前后，公司控股股东持股数额、比例未发生变化，公司控 股股东及实际控制人均未发生变化。 证券代码：600713 证券简称：南京医药 编号：ls2025-115 债券代码：110098 债券简称：南药转债 南京医药股份有限公司 一、本次权益变动基本情况 本次权益变动前，Alliance Healthcare 由 Walgreens Boots Alliance, Inc.（以下 简称 ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Walgreens Boots Alliance, Inc. common stock between April 2, 2020, and January 16, 2025, of the March 31, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Walgreens common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the Court by March 31, 2025 [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in securities class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4]. Group 3: Case Allegations - The lawsuit alleges that Walgreens failed to disclose widespread violations of federal law regarding prescription medication dispensation and reimbursement during the Class Period [5]. - It is claimed that Walgreens' conduct posed a heightened risk of regulatory scrutiny, civil liability, and reputational harm, leading to materially false and misleading public statements [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the unsustainable nature of Walgreens' revenues from unlawful conduct [5].

Core Viewpoint - A class action securities lawsuit has been filed against Walgreens Boots Alliance, Inc. for alleged securities fraud affecting investors between April 2, 2020, and January 16, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that Walgreens made false statements regarding its commitment to regulatory compliance while continuing to violate federal laws related to prescription medication dispensation [2]. - It is alleged that Walgreens' unlawful conduct would lead to increased regulatory scrutiny, civil liability, and reputational damage [2]. - The complaint asserts that Walgreens' revenues from prescription medication sales were unsustainable due to their reliance on illegal activities, rendering the company's public statements materially false and misleading [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until March 31, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - A class action lawsuit has been filed against Walgreens Boots Alliance, Inc. for alleged violations of federal securities laws during the Class Period from April 2, 2020, to January 16, 2025, seeking damages for affected investors [1] Company Overview - Walgreens operates as a healthcare, pharmacy, and retail company in the U.S., U.K., Germany, and internationally, with three reportable segments: U.S. Retail Pharmacy, International, and U.S. Healthcare [4] - The U.S. Retail Pharmacy segment includes retail drugstores, health and wellness services, and specialty and home delivery pharmacy services, with a significant portion of sales derived from prescription drugs reimbursed by third-party payors [4] Legal and Regulatory Context - Walgreens must comply with various federal statutes, including the Controlled Substances Act (CSA) and the False Claims Act (FCA), which govern the dispensation of controlled substances and reimbursement claims [5][6] - The opioid crisis in the U.S. has led to increased scrutiny of Walgreens' practices, with the company previously settling multiple legal claims related to its role in the opioid epidemic [6][7] Allegations and Lawsuit Details - The complaint alleges that Walgreens made materially false and misleading statements regarding its business operations and compliance with federal laws, leading to unsustainable revenues from unlawful conduct [9] - The Department of Justice (DOJ) filed a civil complaint against Walgreens, alleging the company dispensed millions of unlawful prescriptions and sought reimbursement from federal health care programs [10] - Following the DOJ's announcement, Walgreens' stock price fell by 12.06%, indicating a significant market reaction to the allegations [10]

Core Viewpoint - The Gross Law Firm is notifying shareholders of Walgreens Boots Alliance, Inc. regarding a class action lawsuit due to alleged misleading statements and regulatory violations during a specified class period [1]. Group 1: Class Action Details - The class period for the lawsuit is from April 2, 2020, to January 16, 2025 [3]. - Allegations include that Walgreens engaged in widespread violations of federal law related to prescription medication dispensation and reimbursement [3]. - The lawsuit claims that Walgreens' revenues from prescription medication sales were unsustainable due to unlawful conduct, leading to materially false and misleading public statements [3]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by March 31, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - Participation in the case incurs no cost or obligation for shareholders [4]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and illegal business practices [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Viewpoint - A class action securities lawsuit has been filed against Walgreens Boots Alliance, Inc. for alleged securities fraud affecting investors between April 2, 2020, and January 16, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Walgreens made false statements and concealed ongoing violations of federal law regarding prescription medication dispensation and reimbursement [2]. - It is alleged that Walgreens' conduct would lead to increased regulatory scrutiny, civil liability, and reputational damage [2]. - The complaint asserts that Walgreens' revenues from prescription medication sales were unsustainable due to unlawful practices, rendering public statements materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until March 31, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].

Core Insights - Monteverde & Associates PC has successfully recovered millions for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] - The firm is currently investigating Walgreens Boots Alliance, Inc. regarding its proposed merger with Sycamore Partners, where WBA shareholders are set to receive $11.45 and a non-transferable right to receive up to $3.00 in cash per share [1] Company Overview - Monteverde & Associates PC is headquartered in the Empire State Building, New York City, and operates as a national class action securities firm with a strong track record in litigation [2][3] - The firm emphasizes that no company, director, or officer is above the law, and it offers free consultations for shareholders with concerns [3] Legal Context - The firm is involved in class action lawsuits and has a history of recovering funds for shareholders, including cases that have reached the U.S. Supreme Court [2][4] - Shareholders of Walgreens Boots Alliance are encouraged to seek additional information regarding their rights and the ongoing investigation [3]

Core Viewpoint - The law firm Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Walgreens Boots Alliance, Inc. to Sycamore Partners for $11.45 per share in cash, with potential additional cash from future monetization of VillageMD businesses [1][3]. Group 1: Sale Price Concerns - The sale price of $11.45 per share is below the price targets set by at least two Wall Street analysts, even when considering the potential additional $3.00 per share [2][4]. - Analysts Lisa Gill of J.P. Morgan and Charles Rhyee of TD Cowen have set price targets of $15.00 per share, while three other analysts have targets of $12.00 per share [4]. - Several shareholders have expressed disappointment regarding the sale price, with comments indicating feelings of being "robbed" and that it is a "terrible deal for shareholders" [5]. Group 2: Investigation Rationale - The investigation aims to determine if the Walgreens Board of Directors acted in the best interests of shareholders when approving the sale and whether the agreed price is fair [6]. - The investigation will also assess if all material information regarding the transaction has been fully disclosed to shareholders [6]. Group 3: Market Context - The sale price is significantly lower than Walgreens' 52-week high of $22.05, suggesting that the deal may be opportunistic [5].

Table of Contents As filed with the Securities and Exchange Commission on January 17, 2024 Registration No. 333-276348 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BrightSpring Health Services, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 8082 82-2956404 (I ...